These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 2446081

  • 1. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J, Stott DJ, Robertson JI, Ball SG.
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B, Gradin K, Pettersson A, Hedner T.
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [Abstract] [Full Text] [Related]

  • 3. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML, Schenck KW, Kurz KD.
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [Abstract] [Full Text] [Related]

  • 4. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ, Reneman RS.
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [Abstract] [Full Text] [Related]

  • 5. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T, Persson B.
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [Abstract] [Full Text] [Related]

  • 6. Renal hemodynamic effects of ketanserin therapy in essential hypertension.
    Ram CV, Gonzalez DG, Kaplan NM, Ralakis JM, Henderson JD, Lugo CE, Zachariah N.
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S78-80. PubMed ID: 2446078
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of acute and chronic effects of ketanserin in the treatment of hypertension and hypothesis on a new mechanism of action].
    Sechi LA.
    Ann Ital Med Int; 1990; 5(4 Pt 2):433-50. PubMed ID: 2102130
    [Abstract] [Full Text] [Related]

  • 8. [Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension].
    Gambini G, Gradoli C, Proietti MG, Pinchi G, Fioroni E, Valori C.
    Clin Ter; 1989 Jul 31; 130(2):101-7. PubMed ID: 2529082
    [Abstract] [Full Text] [Related]

  • 9. Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
    de Lorenzo A, Ceccanti M, Assogna G, Romeo M, Cavaleri G, Attilia ML.
    Int J Clin Pharmacol Res; 1988 Jul 31; 8(5):321-5. PubMed ID: 3068159
    [Abstract] [Full Text] [Related]

  • 10. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
    Nelson M, Coghlan JP, Denton DA, Tresham JJ, Whitworth JA, Scoggins BA.
    Clin Exp Pharmacol Physiol; 1987 Jul 31; 14(7):555-63. PubMed ID: 3124998
    [Abstract] [Full Text] [Related]

  • 11. Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.
    Smits J, van Dorsten F, Struyker Boudier H.
    Drugs; 1988 Jul 31; 36 Suppl 1():55-60. PubMed ID: 3149239
    [Abstract] [Full Text] [Related]

  • 12. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
    Balasubramaniam G, Lee HS, Mah SC.
    J Pharmacol Exp Ther; 1993 Jan 31; 264(1):129-34. PubMed ID: 8093720
    [Abstract] [Full Text] [Related]

  • 13. [The effect of pharmacologic blockade of serotonin receptors (S2) on arterial pressure in rats with 2 forms of hereditary arterial hypertension].
    Popova NK, Piianzin AI, Markel' AL.
    Farmakol Toksikol; 1989 Jan 31; 52(6):58-61. PubMed ID: 2516487
    [Abstract] [Full Text] [Related]

  • 14. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
    Ikeda K, Takata M, Tomoda F, Mikawa M, Iida H, Sasayama S.
    J Cardiovasc Pharmacol; 1987 Jan 31; 10 Suppl 3():S69-72. PubMed ID: 2446076
    [Abstract] [Full Text] [Related]

  • 15. Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
    Hedner T, Pettersson A, Persson B.
    J Hypertens Suppl; 1986 Apr 31; 4(1):S91-3. PubMed ID: 2939221
    [Abstract] [Full Text] [Related]

  • 16. Specificity of the serotonergic antagonist ketanserin.
    Stott DJ, Robertson JI, Ball SG.
    J Hypertens Suppl; 1985 Dec 31; 3(3):S191-3. PubMed ID: 2856702
    [Abstract] [Full Text] [Related]

  • 17. [Hemodynamic and humoral effects of 2 different doses of ketanserin in aged patients with hypertension].
    Rizzoni D, Castellano M, Beschi M, Agabiti-Rosei E.
    Ann Ital Med Int; 1990 Dec 31; 5(4 Pt 2):489-96. PubMed ID: 2102136
    [Abstract] [Full Text] [Related]

  • 18. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L, Svensson A, Dahlöf B, Eggertsen R, Hansson L.
    Acta Med Scand; 1983 Dec 31; 214(2):125-30. PubMed ID: 6353879
    [Abstract] [Full Text] [Related]

  • 19. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ, Wenting GJ, Man in't Veld AJ, Boomsma F, Schalekamp MA.
    J Cardiovasc Pharmacol; 1985 Dec 31; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [Abstract] [Full Text] [Related]

  • 20. An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats.
    Docherty JR.
    J Pharmacol Exp Ther; 1989 Feb 31; 248(2):736-40. PubMed ID: 2537414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.